Unicycive Therapeutics (Nasdaq:UNCY) has big plans for its lead candidate OLC
Unicycive Therapeutics (Nasdaq:UNCY) is a clinical-stage biotech company based in Los Altos, CA. The company's lead candidate is oxylanthanum carbonate (OLC), a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. In this interview, we talk to Unicycive's CEO Dr Shalabh Gupta about the company's plans to resubmit its New Drug Application for OLC, the superiority of this drug to other treatments for hyperphosphatemia the potential market and the company's commercialisation plans.
